Compositions and methods for inhibition of the JAK pathway

US9732073B2 · kind B2 · utility

Assignee

• Rigel Pharmaceuticals, Inc. · US

Inventors

• Hui Li · Santa Clara, US
• Sambaiah Thota · Fremont, US
• David Carroll · San Francisco, US
• Ankush Argade · Foster City, US
• Kin Tso · San Francisco, US
• Arvinder Sran · Fremont, US
• Jeffrey Clough · Redwood City, US
• Holger Keim · Irvine, US
• Somasekhar Bhamidipati · Foster City, US
• Vanessa Taylor · San Francisco, US
• Robin Cooper · St. Augustine, US
• Rajinder Singh · Belmont, US
• Brian Wong · Singapore, SG

Key dates

• Filing date: Dec 18, 2015
• Grant date: Aug 15, 2017
• Expiry date: Dec 18, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D285/22
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.